BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD 207.00
+2.20 (1.07%)
Nov 26, 2025, 1:45 PM HKT
BeOne Medicines AG Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 35,585 | 27,811 | 17,435 | 9,766 | 7,472 | 2,017 | Upgrade | |
Revenue Growth (YoY) | 53.47% | 59.51% | 78.53% | 30.69% | 270.56% | -32.37% | Upgrade |
Cost of Revenue | 4,878 | 4,336 | 2,694 | 1,976 | 1,048 | 8,915 | Upgrade |
Gross Profit | 30,708 | 23,475 | 14,741 | 7,790 | 6,425 | -6,899 | Upgrade |
Selling, General & Admin | 14,587 | 13,371 | 10,699 | 8,819 | 6,290 | 3,918 | Upgrade |
Research & Development | 14,899 | 14,257 | 12,612 | 11,315 | 9,270 | - | Upgrade |
Amortization of Goodwill & Intangibles | - | - | - | - | 4.76 | 5.52 | Upgrade |
Operating Expenses | 29,385 | 27,628 | 23,311 | 20,134 | 15,565 | 3,924 | Upgrade |
Operating Income | 1,323 | -4,153 | -8,570 | -12,344 | -9,140 | -10,822 | Upgrade |
Interest Expense | -104.91 | -107.56 | -29.99 | -131.77 | -179.2 | -117.33 | Upgrade |
Interest & Investment Income | 286.42 | 456.72 | 554.78 | 493.74 | 79.1 | 130.37 | Upgrade |
Earnings From Equity Investments | -73.15 | -75 | -55.71 | -25.4 | -11.41 | -3.21 | Upgrade |
Other Non Operating Income (Expenses) | -94.28 | 53.66 | -279.99 | -1,346 | 52.82 | 166.49 | Upgrade |
EBT Excluding Unusual Items | 1,337 | -3,825 | -8,381 | -13,353 | -9,198 | -10,646 | Upgrade |
Gain (Loss) on Sale of Investments | -52.65 | -64.98 | -48.74 | -172.69 | 59.63 | 81.47 | Upgrade |
Gain (Loss) on Sale of Assets | -2.89 | - | - | - | - | - | Upgrade |
Other Unusual Items | - | - | 2,573 | - | - | - | Upgrade |
Pretax Income | 1,160 | -3,890 | -5,856 | -13,526 | -9,139 | -10,565 | Upgrade |
Income Tax Expense | 925.11 | 815.93 | 396.18 | 295.05 | 122.15 | 67.88 | Upgrade |
Earnings From Continuing Operations | 234.93 | -4,706 | -6,252 | -13,821 | -9,261 | -10,632 | Upgrade |
Minority Interest in Earnings | - | - | - | - | - | 23.61 | Upgrade |
Net Income | 234.93 | -4,706 | -6,252 | -13,821 | -9,261 | -10,609 | Upgrade |
Net Income to Common | 234.93 | -4,706 | -6,252 | -13,821 | -9,261 | -10,609 | Upgrade |
Shares Outstanding (Basic) | 108 | 105 | 104 | 103 | 93 | 83 | Upgrade |
Shares Outstanding (Diluted) | 112 | 105 | 104 | 103 | 93 | 83 | Upgrade |
Shares Change (YoY) | 7.37% | 0.86% | 1.22% | 11.15% | 11.16% | 38.99% | Upgrade |
EPS (Basic) | 2.18 | -44.70 | -59.89 | -134.01 | -99.81 | -127.09 | Upgrade |
EPS (Diluted) | 2.10 | -44.70 | -59.89 | -134.01 | -99.81 | -127.09 | Upgrade |
Free Cash Flow | 3,488 | -4,622 | -12,192 | -12,567 | -9,921 | -9,146 | Upgrade |
Free Cash Flow Per Share | 31.11 | -43.90 | -116.79 | -121.85 | -106.92 | -109.57 | Upgrade |
Gross Margin | 86.29% | 84.41% | 84.55% | 79.77% | 85.98% | - | Upgrade |
Operating Margin | 3.72% | -14.93% | -49.15% | -126.40% | -122.31% | -536.69% | Upgrade |
Profit Margin | 0.66% | -16.92% | -35.86% | -141.52% | -123.93% | -526.10% | Upgrade |
Free Cash Flow Margin | 9.80% | -16.62% | -69.93% | -128.68% | -132.76% | -453.57% | Upgrade |
EBITDA | 2,377 | -2,934 | -7,975 | -11,909 | -8,851 | -10,615 | Upgrade |
EBITDA Margin | 6.68% | -10.55% | -45.74% | -121.94% | -118.44% | - | Upgrade |
D&A For EBITDA | 1,054 | 1,219 | 595.18 | 434.89 | 288.99 | 207.54 | Upgrade |
EBIT | 1,323 | -4,153 | -8,570 | -12,344 | -9,140 | -10,822 | Upgrade |
EBIT Margin | 3.72% | -14.93% | -49.15% | -126.40% | -122.31% | - | Upgrade |
Revenue as Reported | 27,126 | 27,811 | 17,435 | 9,766 | 7,472 | 2,017 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.